Institution statistics

JANSSEN PHARMACEUTICA N.V. - BE 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:200-300
Total Project Funding per Partner:> 1000
Total Number of Projects:100-200
2018
Criterium:Position:
Overall Score:800-900
Total Project Funding per Partner:> 1000
Total Number of Projects:400-500
Networking Rank (Reputation):700-800
2017
Criterium:Position:
Overall Score:500-600
Total Project Funding per Partner:500-600
Total Number of Projects:500-600
Networking Rank (Reputation):400-500
2016
Criterium:Position:
Overall Score:800-900
Networking Rank (Reputation):700-800
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 66
As coordinator: 1
As participant: 65
Sole participant: 0
Coordinator / Participant Ratio: 0.02*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 103.198.703 255.250 3
2019 0 227.020.318 681.640 21
2018 2.054.499 164.854.672 134.531 1 6
2017 0 100.465.984 1.270.035 12
2016 0 82.314.814 430.674 11
2015 0 11.045.925 501.120 3
2013 0 7.662.742 733.990 2
2011 0 2.906.854 223.630 1
2010 0 3.162.416 264.000 1
2009 0 2.329.000 332.714 1
2008 0 3.598.626 359.863 1
2005 0 11.998.527 285.679 1
2003 0 1.217.913 135.324 1
2001 0 514.927 57.214 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
NOVARTIS PHARMA24
ELI LILLY AND COMPANY LIMITED19
PFIZER LIMITED19
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD19
F HOFFMANNLA ROCHE17
UCB BIOPHARMA14
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT13
KATHOLIEKE UNIVERSITEIT LEUVEN13
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM12
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL12
TAKEDA DEVELOPMENT CENTRE EUROPE12
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE11
ASTRAZENECA AB10
CHARITE UNIVERSITAETSMEDIZIN BERLIN10
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE10
KING'S COLLEGE LONDON10
SANOFIAVENTIS10
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V9
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER9
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN9
NOVO NORDISK9
STICHTING VUMC9
ABBVIE INC8
BAYER AKTIENGESELLSCHAFT8
H LUNDBECK AS8
KAROLINSKA INSTITUTE8
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT8
THE UNIVERSITY OF EDINBURGH8
UNIVERSITY COLLEGE LONDON8
UNIVERSITY OF NEWCASTLE UPON TYNE8
ACADEMISCH ZIEKENHUIS GRONINGEN7
BAYER7
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG7
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE7
STICHTING KATHOLIEKE UNIVERSITEIT7
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE7
UNIVERSITAIR MEDISCH CENTRUM UTRECHT7
UPPSALA UNIVERSITET7
ALZHEIMER EUROPE6
ASTRAZENECA6
EUROPEAN PATIENTS' FORUM6
INSTITUT DE RECHERCHES SERVIER6
MEDIZINISCHE UNIVERSITAET WIEN6
STICHTING LYGATURE6
UNIVERSITY OF DUNDEE6
ACADEMISCH ZIEKENHUIS LEIDEN5
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE5
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN5
MERCK SHARP & DOHME CORP5
ORION OYJ5
SANOFIAVENTIS DEUTSCHLAND5
THE UNIVERSITY OF MANCHESTER5
UNIVERSITEIT ANTWERPEN5
UNIVERSITY OF COPENHAGEN5
UNIVERSITY OF GLASGOW5
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS4
BAYER PHARMA4
BIOGEN IDEC LIMITED4
COMMISSARIAT A L'ENERGIE ATOMIQUE4
EUROPEAN CANCER PATIENT COALITION4
EUROPEAN MOLECULAR BIOLOGY LABORATORY4
GOETEBORGS UNIVERSITET4
LEIDS UNIVERSITAIR MEDISCH CENTRUM4
RIJKSUNIVERSITEIT GRONINGEN4
SERVICIO MADRILENO DE SALUD4
TEVA PHARMACEUTICAL INDUSTRIES LIMITED4
THE HYVE BV4
THE UNIVERSITY OF LIVERPOOL4
THE UNIVERSITY OF SHEFFIELD4
UNIVERSITE DE GENEVE4
UNIVERSITEIT GENT4
UNIVERSITEIT MAASTRICHT4
UNIVERSITY OF BOLOGNA4
ABBVIE DEUTSCHLAND GMBH & CO KG3
ARTTIC3
ASTELLAS PHARMA EUROPE BV3
BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION3
CELGENE MANAGEMENT SARL3
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE3
COVANCE LABORATORIES3
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV3
EBERHARD KARLS UNIVERSITAET TUEBINGEN3
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK3
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS3
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE3
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL3
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON INSTITUT DE RECERCA3
FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM3
INSTITUT PASTEUR3
JOHANN WOLFGANG GOETHEUNIVERSITATFRANKFURT AM MAIN3
JOHNSON MATTHEY PLC3
KLINIKUM DER UNIVERSITAET ZU KOELN3
LEIDEN UNIVERSITY3
LUNDS UNIVERSITET3
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV3
OSPEDALE PEDIATRICO BAMBINO GESU3
SEMMELWEIS EGYETEM3
SIB INSTITUT SUISSE DE BIOINFORMATIQUE3
STICHTING BURO ECNP3
TTOPSTART BV3
Constancy:

Total number of partners:1424

Partner loyalty:
Frequent Partner: (> 2 projects): 678
Rare Partner: 746

Frequent / Rare Partner Ratio: 0.91

Diversity:

Categories:
Category:No:
RTD HORIZONTAL TOPICS5
BIOLOGICAL SCIENCES4
SOCIAL AND ECONOMIC CONCERNS4
INDUSTRY AND TECHNOLOGY2
PROTECTING MAN AND HIS ENVIRON1

Project overview:

Start dateProjectacronymrolefundingpartners
2020-05-01Process Analytical Technology Tools for Real-Time Physical and Chemical Characterization of Nanosuspensions PAT4Nanoparticipant5.092.4099
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69428
2020-01-01EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS ERA4TBparticipant89.815.60031
2019-11-01EU Patient- cEntric clinicAl tRial pLatform EU-PEARLparticipant12.004.95336
2019-11-01Collaboration for Prevention and Treatment of MDR Bacterial Infections COMBINEparticipant8.000.00011
2019-11-01Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases IDEA-FASTparticipant20.997.52346
2019-10-01A Centre of Excellence in Computational Biomedicine CompBioMed2participant7.992.82316
2019-10-01Long Acting Medicines for Complex Therapeutics Needed Now LongActNowparticipant1.292.9013
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00022
2019-09-01Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials Trials@Homeparticipant19.036.99831
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-06-01MachinE Learning Ledger Orchestration for Drug DiscoverY MELLODDYparticipant8.000.00017
2019-05-01Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs RespiriNTMparticipant5.687.9849
2019-05-01Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors RespiriTBparticipant6.840.0009
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-04-01The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use VALUE-Dxparticipant6.799.10026
2019-03-01Efficiently Networking European Neurodegeneration Research NEURONETparticipant1.199.12510
2019-03-01Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts IMMUcanparticipant17.830.00028
2019-03-01EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells EBiSC2participant4.599.64816
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2019-01-01Remote Assessment of Disease and Relapse – Alzheimer’s Disease RADAR-ADparticipant4.999.75716
2019-01-01Multiscale Analysis of Thermomechanical Behaviour of Granular Materials MatheGramparticipant4.170.17815
2019-01-01FAIRplus FAIRplusparticipant3.996.15022
2019-01-01Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain IM2PACTparticipant9.000.00027
2018-12-01European Screening Centre; Unique Library for Attractive Biology ESCulabparticipant18.249.99320
2018-11-01Artificial Intelligence to transform Drug and Chemical safety testing PATH-TOXcoordinator2.054.4993
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-06-01Autism Innovative Medicine Studies – 2 – Trials AIMS-2-TRIALSparticipant54.999.99948
2018-05-01Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope PIONEERparticipant6.000.00035
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00048
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-10-01Memory research: Ground-breaking, Applied, and Technological Exchanges M-GATEparticipant3.961.16011
2017-09-01Personalised In-Silico Cardiology PICparticipant4.000.56919
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-09-01Interdisciplinary training network on the purinergic P2X7 receptor to control neuroinflammation and hyperexcitability in brain diseases. PurinesDXparticipant3.487.46321
2017-09-01Rheuma Tolerance for Cure RTCureparticipant6.000.00020
2017-03-01Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 IMPRiNDparticipant4.684.99819
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2017-01-01Solid Catalysts for activation of aromatic C-H bonds H-CCATparticipant7.588.31310
2017-01-01REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 RESCEUparticipant14.498.12518
2017-01-01Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 TransQSTparticipant8.000.00023
2016-11-01Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 PHAGOparticipant8.838.00020
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-10-01A Centre of Excellence in Computational Biomedicine CompBioMedparticipant4.938.21616
2016-10-01Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952 AMYPADparticipant11.999.88615
2016-10-01A global alliance for Zika virus control and prevention ZIKAllianceparticipant11.964.20956
2016-10-01Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975 ADAPTEDparticipant3.510.00014
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033

overview shows latest 50 from 66 projects (2000-01-01 - 2020-12-31)
A full list of projects can be found here:
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum